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Fluorescent	  protein-­‐encapsulated	  gold	  nanoclusters	  (AuNCs)	  offer	  a	  non-­‐toxic	  means	  of	  
sensing	   and	   imaging	   biological	   phenomena	   on	   the	   nanoscale.	   However,	   the	  
biofunctionality	  of	  proteins	  encapsulating	  AuNCs	  has	  not	  been	  fully	  elucidated	  to	  date.	  
Here	  we	  studied	  the	  biofunctionality	  of	  the	  second	  major	  drug	  binding	  site	  (Sudlow	  II)	  
of	  Human	  Serum	  Albumin	   (HSA)	  encapsulated	  AuNCs	  after	  AuNC	   synthesis.	   L-­‐Dopa,	   a	  
fluorescent	  drug	  molecule	  associated	  with	  the	  clinical	  treatment	  of	  Parkinson’s	  disease,	  
which	  commonly	  binds	   to	   the	  Sudlow	   II	   site,	  was	  used	   to	  study	   the	  availability	  of	   the	  
site	   before	   and	   after	   AuNC	   synthesis	   through	   changes	   to	   its	   fluorescence	  
characteristics.	   L-­‐Dopa	  was	  observed	  using	   its	   intrinsic	   fluorescence	   to	   readily	  bind	   to	  
HSA-­‐AuNCs	   complexes.	   Interestingly,	   the	   fluorescence	   emission	   intensity	   of	   AuNCs	  
linearly	   increased	  with	   L-­‐Dopa	   concentration	  while	   exciting	   the	   AuNC	   directly	   at	   470	  
nm,	  Using	  a	  400	  nM	  HSA-­‐AuNC	  solution,	  L-­‐Dopa	  was	  rapidly	  detected	  at	  a	  limit	  of	  300	  
pM,	  indicating	  that	  HSA-­‐AuNCs	  fluorescence	  is	  extremely	  sensitive	  to	  molecular	  binding	  
at	   the	  Sudlow	   II	  binding	   site.	  Future	   research	  may	  be	  able	   to	  utilize	   this	   sensitivity	   to	  
improve	   the	   fluorescence	   characteristics	  of	  AuNCs	  within	  HSA-­‐AuNCs	   for	   imaging	  and	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Serum	   Albumin	   encapsulated	   gold	   nanoclusters	   (AuNCs)	   are	   a	   new	   class	   of	  
fluorophore	  which	  have	  several	  benefits	  in	  comparison	  to	  conventional	  aromatic	  dye	  
fluorophores	  and	  have	  been	  increasingly	  studied	  and	  developed	  in	  recent	  years[1–8].	  
They	   are	   highly	   stable,	   non-­‐toxic[9],	   non-­‐photobleaching[10],	   have	   extremely	   long	  
fluorescent	   lifetimes[11],	   possess	   a	   large	   Stoke-­‐shift	   and	   emit	   in	   the	   red-­‐near	   IR	  
regime[12].	   The	   latter	   minimises	   endogenous	   fluorescence,	   reduces	   Rayleigh	  
scattering	   and	   permits	  work	   in	   the	   therapeutic	  window	  of	   tissue	   and	   cells.	   Due	   to	  
these	   qualities,	   protein	   encapsulated	   AuNCs	   have	   significant	   potential	   as	   a	  
fluorescent	  label	  in	  biomedical	  imaging	  and	  sensing[13–15].	  To	  exploit	  this	  potential	  
it	   is	  essential	   to	  understand	   the	  effects	  AuNC	   formation	  has	  on	  natural	  protein	  bio	  
functionality.	   Human	   Serum	   Albumin	   (HSA)	   is	   the	   major	   plasma	   protein	   with	   vital	  
functions	  acting	  as	  a	  molecular	  depot	  and	  carrier	  via	  	  two	  major	  binding	  sites	  (Sudlow	  
I	  and	  II)[16].	  Much	  effort	  has	  been	  made	  to	  elucidate	  nanoscale	  biological	  processes	  
and	  dynamics	   in	  order	   to	   improve	  disease	  diagnostics	  and	   therapy	  via	   fluorescence	  
and	   Raman	   based	   techniques[17–23].	   With	   a	   better	   understanding	   of	   molecular	  
transport	  within	  the	  body	  via	  nanoscale	  imaging	  and	  sensing,	  therapeutic	  treatments	  
for	   specific	   diseases	   where	   drugs	   must	   be	   delivered	   to	   specific	   sites,	   such	   as	  
Parkinson’s,	  can	  be	  more	  intelligently	  developed	  for	  increased	  effectiveness[24–26].	  
	  
Previously,	  we	  have	  disclosed	  the	  location	  of	  AuNCs	  within	  HSA,	  taking	  advantage	  of	  
Forster	  Resonance	  Energy	  Transfer	  (FRET)	  between	  the	  single	  tryptophan	  of	  HSA	  and	  
the	   encapsulated	   AuNC	   in	   conjunction	  with	  molecular	   dynamics	   simulations[27].	   It	  
was	  discovered	  that	  the	  AuNCs	  are	  bound	  to	  cysteine	  residues	  within	  a	  hydrophobic	  
pocket	   located	   in	   domain	   IIB	   of	   the	   HSA	   protein,	   near	   the	   Sudlow	   I	   major	   drug	  
binding	  site.	  Further	  studies	  found	  that	  the	  model	  binding	  drug,	  warfarin,	  could	  not	  
occupy	   the	   Sudlow	   I	   binding	   site	   at	   the	   same	   time	   as	   an	   AuNC	  was	   bound	   to	   the	  
protein,	  indicating	  that	  the	  proximity	  of	  AuNCs	  affects	  the	  Sudlow	  I	  binding	  site[28].	  
This	   raised	   further	   questions	   as	   to	   how	   the	   second	   Sudlow	   drug	   binding	   site	   was	  
affected	   by	   the	   presence	   of	   a	   bound	   AuNC.	   Yeggoni	   and	   Subramanyam	   previously	  
reported	  on	   the	   interactions	   of	   L-­‐Dopa	  with	  HSA	   (Kd	   =	   4.3	   x	   10-­‐5	  M)	   using	   intrinsic	  
fluorescence	   spectroscopy	   [29].	   It	   was	   shown	   that	   L-­‐Dopa	   upon	   binding	   to	   the	  
Sudlow	   II	   site	   quenched	   the	   fluorescence	   emission	   of	   tryptophan	   from	   the	   HSA	  
protein	   and	   caused	   a	   decrease	   in	   the	   α-­‐helical	   content	   of	   the	   protein.	   Thus,	   the	  
binding	  of	  L-­‐Dopa	  to	  HSA	  can	  be	  detected	  via	  this	  tryptophan	  emission	  quenching.	  	  In	  
this	  work,	  we	  investigated	  the	  binding	  of	  L-­‐Dopa	  to	  the	  HSA-­‐AuNC	  and	  any	  effect	  the	  
binding	  may	  have	  on	  the	  emission	  from	  the	  AuNC.	  The	  increasing	  HSA-­‐AuNC	  emission	  




Materials	  and	  Methods:	  
	  
The	   synthesis	   of	   HSA-­‐AuNCs	   was	   carried	   using	   Xie’s	   method[1].	   All	   synthesised	  
samples	  were	  then	  dialysed	  into	  PBS	  buffer	  solution,	  using	  10	  kDa	  dialysis	  cassettes.	  
All	  chemicals	  were	  purchased	  from	  Sigma-­‐Aldrich.	  All	  dilutions	  were	  carried	  out	  using	  
PBS	  buffer.	  L-­‐Dopa	  solutions	  were	  made	  fresh	  for	  each	  experiment,	  diluted	  in	  purified	  
water.	   Fluorescence	   emission	   spectra	  were	  measured	   using	   a	   HORIBA	   Fluorolog	   3.	  
Fluorescence	   lifetimes	   were	   measured	   using	   the	   Time	   Correlated	   Single	   Photon	  
Counting	  (TCSPC)	  technique	  on	  a	  Horiba	  Deltaflex	  fluorometer.	  A	  time	  range	  of	  13	  µs	  
and	   excitation	  with	   a	   482	   nm	  Delta	   Diode	   or	   279	   nm	   pulsed	   LED	  was	   used	   for	   all	  




Results	  and	  Discussion:	  
	  
	   3	  
	  
Figure	  1	  displays	   the	  normalized	   fluorescence	  emission	   spectra	  of	   L-­‐Dopa,	  HSA	  and	  
HSA-­‐AuNCs.	  The	  excitation	  wavelength	  used	  and	  emission	  peak	  for	  each	  fluorescent	  
molecule	  was	  (ex	  280	  nm,	  em	  320	  nm),	  (ex	  290	  nm,	  em	  320	  nm)	  and	  (ex	  290	  nm,	  em	  
680	  nm)	  respectively.	  L-­‐Dopa’s	  ability	  to	  bind	  to	  HSA	  and	  HSA-­‐AuNCs	  was	  studied	  by	  
introducing	   free	   L-­‐Dopa	   in	   solution	   with	   HSA	   and	   HSA-­‐AuNCs	   independently.	   The	  
emission	   intensity	   of	   tryptophan	   at	   320	   nm	   was	   found	   quenched	   upon	   the	  
introduction	  of	  L-­‐Dopa	  up	  a	  concentration	  of	  40	  µM	  in	  both	  cases	  of	  HSA	  and	  HSA-­‐
AuNCs.	  Upon	  increasing	  the	  L-­‐Dopa	  concentration	  further,	  the	  emission	  was	  seen	  to	  
increase	   due	   to	   the	   influence	   of	   free	   L-­‐Dopa	   fluorescing	   in	   solution,	   despite	   the	  
excitation	  of	  290	  nm	  used,	  as	  shown	  in	  Figure	  2.	  
	  
	  
Figure	   1:	   Normalized	   fluorescence	   emission	   spectra	   of	   L-­‐Dopa	   (solid	   black	   curve),	   HSA	   (dashed	   red	   curve)	   and	  










































Figure	  2:	  Normalized	  peak	   fluorescence	   intensity	  of	   L-­‐Dopa	   in	   solution	  with	  40	  µM	  of	  HSA	   (red)	   and	   L-­‐Dopa	   in	  
solution	  with	  40	  µM	  of	  HSA-­‐AuNCs	  (black).	  Excitation	  wavelength	  of	  290	  nm,	  emission	  wavelength	  of	  325	  nm.	  
	  
	  
The	  quenching	  in	  both	  cases	  agrees	  well	  with	  Yeggoni	  and	  Subramanyam,	  indicating	  
that	  L-­‐Dopa	   is	  bound	   to	   the	  Sudlow	  site	   II[29].	  Thus,	   the	  synthesis	  of	  AuNCs	  within	  
HSA	   does	   not	   hinder	   the	   binding	   affinity	   of	   this	   site.	   The	   increase	   in	   fluorescence	  
intensity	  of	  HSA-­‐AuNCs	  is	  attributed	  to	  free	  dye	  in	  solution;	  since	  at	  40	  µM	  of	  L-­‐Dopa	  
in	  solution	  the	  ratio	  between	  L-­‐Dopa	  and	  HSA	  protein	   is	  1:1	  and	  no	  further	  binding	  
occurs	  at	  a	  higher	  molecular	  ratio	  once	  all	  available	  Sudlow	  II	  sites	  are	  taken.	  	  
Since	  L-­‐Dopa	  acts	  as	  a	  static	  quencher	  to	  tryptophan	  fluorescence	  emission[30],	  the	  
effects	   of	   quenching	   on	   the	   Forster	   Resonance	   Energy	   Transfer	   (FRET)	   between	  
tryptophan	  and	  the	  AuNCs	  was	  studied	   in	  more	  detail.	  The	   increased	  concentration	  
of	  L-­‐Dopa,	  and	  subsequent	  binding	   to	  HSA	  resulted	   in	  a	  diminished	  energy	   transfer	  
from	   tryptophan	   to	   AuNCs;	   observed	   via	   a	   decrease	   in	   the	   emission	   intensity	   of	  
AuNCs	  when	  excited	  at	  290	  nm.	  Interestingly,	  the	  fluorescence	  maximum	  intensity	  of	  
HSA-­‐AuNCs	  when	  excited	  at	  470	  nm	  increases	  until	  a	  ratio	  of	  1:1	  between	  HSA-­‐AuNCs	  
and	  L-­‐Dopa	  is	  reached.	  No	  further	  enhancement	  of	  the	  AuNCs	  fluorescence	  emission	  




















Figure	   3:	   Normalized	   peak	   fluorescence	   intensity	   of	   AuNCs	   (40	   µM)	   as	   a	   function	   of	   increasing	   L-­‐Dopa	  




The	   fluorescence	   lifetimes	  associated	  with	  HSA-­‐AuNCs	  were	  also	   studied	   to	   further	  
understand	   the	   effect	   L-­‐Dopa	  binding	  has	   on	   the	  AuNC	   fluorescence	   emission.	   The	  
fluorescence	   decay	   was	   measured	   using	   TCSPC	   required	   3-­‐exponential	   fitting	   to	  
describe	  the	  data,	  as	  previously	  reported[27].	  The	  fluorescence	  decay	  curve	  for	  HSA-­‐
AuNCs	  when	  exciting	  at	  482	  nm	  is	  shown	  in	  Figure	  4	  as	  an	  example.	  
	  
Figure	  4.	  Fluorescence	  decay	  curve	  of	  HSA-­‐AuNCs	  over	  a	  time	  range	  of	  13	  ms.	  Excitation	  482	  nm,	  emission	  680	  nm	  with	  the	  
residuals	  of	  a	  3	  exponential	  fitting	  to	  the	  decay	  curve.	  Time	  Calibration	  of	  3.327	  ns/channel.	  Peak	  position	  at	  channel	  10.	  
The	  lifetimes	  were	  studied	  both	  by	  excitation	  at	  279	  nm	  via	  FRET	  from	  tryptophan	  to	  
AuNCs,	  and	  directly	  exciting	  the	  AuNCs	  at	  482	  nm.	  In	  both	  cases	  τ1	  is	  small	  and	  does	  
not	  change.	  This	  component	  arises	  from	  measured	  scattered	   light[31]	  and	  accounts	  
for	   1-­‐2	   %	   of	   the	   total	   relative	   amplitude	   of	   the	   decay.	   The	   two	   long	   lifetime	  
components,	  τ2	  =	  ~1	  µs	  and	  τ3	  =	  ~2	  µs,	  are	  attributed	  to	  the	  AuNCs	  and	  agree	  with	  
previous	   reports[32].	   As	   L-­‐Dopa	   concentration	   increases,	   the	   fluorescence	   lifetime,	  
τ3,	  is	  seen	  to	  increase	  by	  0.1-­‐0.2	  µs,	  depending	  on	  the	  excitation	  source.	  This	  increase	  
in	  fluorescence	  lifetime	  also	  coincided	  with	  a	  decrease	  in	  the	  relative	  amplitude	  and	  
	   6	  
the	   percentage	   of	   overall	   counted	   photons	   (a3)	   associated	   with	   τ3.	   Since	   τ1	   is	  
scattered	  light	  and	  the	  photons	  collected	  are	  proportional	  to	  the	  measurement	  time,	  
the	  decrease	   in	   the	   relative	   intensity	   of	  τ3	   had	  no	  effect	   on	  τ1,	   but	   resulted	   in	   the	  
relative	  intensity	  and	  percentage	  of	  overall	  counts	  (a2)	  attributed	  to	  the	  τ2	  increase.	  
The	  observed	  changes	  in	  τ2	  and	  τ3	  are	  not	  dependent	  on	  the	  excitation	  wavelength,	  
showing	  that	  the	  binding	  of	  L-­‐Dopa	  to	  the	  Sudlow	  site	  II	  can	  directly	  affect	  the	  triplet	  
states	  and	  decay	  process	  of	  AuNCs.	  To	  further	  understand	  how	  AuNCs	  are	  affected	  by	  
molecules	  binding	  at	  Sudlow	  Site	  II,	  synthesis	  of	  AuNCs	  was	  carried	  out	  with	  L-­‐Dopa	  
prebound	   to	   HSA.	   The	   fluorescence	   emission	   of	   HSA-­‐AuNCs	  was	  monitored	   during	  
the	  synthesis.	  For	  AuNC	  synthesis	  using	  native	  HSA	  a	  fluorescence	  emission	  peak	  at	  




















Figure	  5:	  A	  -­‐	  Fluorescence	  emission	  spectra	  of	  HSA-­‐AuNCs	  during	  synthesis.	  0	  hours	  (black),	  2	  hours	  (red),	  4	  hours	  
(blue)	  and	  6	  hours	  (pink).	  Excitation	  wavelength	  of	  470	  nm.	  B	  -­‐	  Peak	  fluorescence	  emission	  of	  HSA-­‐AuNCs	  (with	  
and	  without	  L-­‐Dopa	  pre-­‐bound	  to	  HSA)	  during	  synthesis.	  Emission	  maximum	  of	  HSA-­‐AuNCs	  at	  525	  nm	  (black)	  and	  
at	   680	  nm	   (red).	   Emission	  maximum	  of	   L-­‐Dopa-­‐HSA-­‐AuNCs	  at	  525	  nm	   (green)	   and	  at	  680	  nm	   (blue).	   Excitation	  
wavelength	  of	  470	  nm	  in	  all	  cases	  
	  
	  
	  This	   peak	   has	   previously	   been	   attributed	   to	   small	   intermediate	   AuNCs	  
forming[28,32].	   Over	   time	   this	   peak	   decreases	   as	   the	   cluster	   size	   increases	   and	  
fluorescence	   emission	   at	   680	   nm	   increases.	   Both	   fluorescence	   peaks	  were	   tracked	  
during	   the	   synthesis	   of	   HSA-­‐AuNCs	   with	   L-­‐Dopa	   prebound	   and	   compared	   to	   the	  
native	   HSA.	   It	   was	   found	   that	   prebound	   L-­‐Dopa	   does	   not	   affect	   the	   synthesis	   of	  
AuNCs	   in	   HSA.	   This	   adds	   further	   evidence	   that	   the	   Sudlow	   II	   binding	   site	   is	  
independent	  of	   the	  AuNC	  binding	  site	  and	  does	  not	  play	  a	   role	   in	   the	   formation	  of	  
AuNCs,	  unlike	  the	  Sudlow	  site	  I[28].	  To	  quantify	  the	  L-­‐Dopa	  detection	  limits	  of	  HSA-­‐
AuNCs	  the	  concentration	  of	  HSA-­‐AuNCs	  was	  diluted	  to	  400	  nM.	  Sequential	  additions	  
of	   20	   nM	   of	   L-­‐Dopa	   was	   added	   to	   the	   HSA-­‐AuNC	   solution	   and	   the	   fluorescence	  
emission	   of	   AuNCs	   (excitation	   470	   nm,	   emission	   680	   nm)	  was	  measured.	   A	   nearly	  
linear	  relationship	  was	  found	  between	  0	  -­‐	  200	  nM	  of	  L-­‐Dopa	  and	  AuNC	  emission,	  as	  
































Figure	  6:	  L-­‐Dopa	  concentration	  as	  a	  function	  of	  fluorescence	  emission	  of	  HSA-­‐AuNCs	  (400	  nM),	  excitation	  470	  nm,	  
emission	  680	  nm.	  A	  linear	  fit	  was	  applied	  to	  the	  data	  set	  with	  a	  gradient	  of	  7.7	  ±	  0.6	  x	  10-­‐3.	  
	  
The	   linear	  relationship	  was	  seen	  to	   fall	  away	  and	  the	   fluorescence	  enhancement	  of	  
AuNCs	   had	   diminishing	   returns	   above	   200	   nm,	   as	   seen	   for	   the	   initial	   interaction	  
studies	  in	  Figure	  3.	  Again,	  we	  observed	  that	  the	  enhancement	  only	  takes	  place	  when	  
the	   protein	   to	   L-­‐Dopa	   molecule	   is	   less	   than	   2:1,	   indicating	   that	   the	   formation	   of	  
dimers	  upon	  AuNC	  synthesis	  has	  a	  direct	  effect	  on	  the	  number	  of	  Sudlow	  II	  binding	  
sites	  available	  for	  L-­‐Dopa	  binding.	  The	  limit	  of	  detection	  (LOD)	  was	  found	  to	  be	  300	  
pM,	   for	   a	  HSA-­‐AuNC	   concentration	   of	   400	   nM.	   Since	   the	   dynamic	   range	   is	   directly	  
linked	   to	   the	   protein/L-­‐dopa	   ratio,	   it	   is	   possible	   to	   shift	   the	   dynamic	   range	   to	  
accommodate	  the	  L-­‐Dopa	  concentration	  of	  interest.	  To	  show	  that	  the	  dynamic	  range	  
can	  be	  tailored	  via	  HSA-­‐AuNC	  concentration	  we	  increased	  the	  concentration	  of	  HSA-­‐




















Figure	  7:	  L-­‐Dopa	  concentration	  as	  a	  function	  of	  fluorescence	  emission	  of	  HSA-­‐AuNCs	  (4	  µM),	  excitation	  470	  nm,	  
and	  emission	  680	  nm.	  A	  linear	  fit	  was	  applied	  to	  the	  data	  set	  with	  a	  gradient	  of	  2.9	  ±	  0.3	  x	  10-­‐6	  µMµA/CPS	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In	  this	  case,	  the	  dynamic	  range	  was	  found	  to	  be	  between	  0	  –	  2	  µM;	  again,	  showing	  
the	   same	   behaviour	   at	   L-­‐Dopa	   concentrations	   higher	   than	   the	   2:1	   protein/L-­‐Dopa	  
ratio.	   For	   a	   4	   µM	   concentration,	   the	   LOD	   was	   found	   to	   be	   340	   nM.	   The	   same	  
experiment	  was	  applied	  to	  HSA-­‐AuNC	  solution	  with	  a	  concentration	  of	  40	  µM,	  again	  





We	  have	  disclosed	  that	  the	  Sudlow	  II	  binding	  site	   located	   in	  domain	  IIIA	  of	  the	  HSA	  
protein	  is	  active	  after	  the	  encapsulation	  of	  AuNCs.	  L-­‐Dopa	  was	  found	  to	  successfully	  
bind	   to	   Sudlow	   site	   II	   in	   the	   presence	   of	   the	   AuNCs,	   confirmed	   by	   a	   characteristic	  
decrease	  in	  the	  intrinsic	  protein	  fluorescence	  intensity.	  It	  was	  also	  found	  that	  AuNCs	  
could	  be	  synthesised	  within	  HSA	  that	  already	  had	  L-­‐Dopa	  pre-­‐bound,	  suggesting	  that	  
the	  Sudlow	  II	  binding	  site	  does	  not	  play	  a	  role	  in	  AuNC	  formation,	  unlike	  the	  Sudlow	  I	  
binding	  site.	  It	  was	  also	  observed	  that	  the	  fluorescence	  characteristics	  of	  AuNCs	  are	  
directly	   affected	   by	   the	   binding	   of	   L-­‐Dopa	   to	   the	   protein.	   The	   decrease	   in	  
fluorescence	   intensity	   as	   a	   function	   of	   L-­‐Dopa	   concentration	   combined	   with	   the	  
increase	  in	  fluorescence	  lifetime	  under	  279	  nm	  excitation	  suggests	  that	  a	  complex	  is	  
formed	   between	   the	   two	   fluorescent	   molecules	   and	   reduced	   FRET	   between	  
tryptophan	  and	  the	  AuNC.	  Future	  studies	  into	  improving	  the	  fluorescence	  emission	  of	  
HSA-­‐AuNCs	  may	  concentrate	  on	  utilising	  the	  Sudlow	  II	  binding	  site.	  The	  relationship	  
between	  HSA-­‐AuNC	  and	  L-­‐Dopa	  concentration	  below	  a	  ratio	  of	  2:1	  was	  found	  to	  be	  
nearly	   linear,	   and	   as	   such,	   could	   be	   used	   as	   a	   means	   of	   quantifying	   L-­‐Dopa	  
concentrations	   in	   solution	   via	   a	   quick	   and	   simple	  measurement	   of	   AuNC	   emission	  
intensity.	  We	  have	  shown	  that	  the	  lowest	  limit	  of	  detection	  is	  sub	  nanomolar,	  with	  a	  
value	  of	  300	  pM	  and	  as	  a	  rule	  of	  thumb,	  the	  limit	  of	  detection	  has	  always	  been	  lower	  
than	   1/100th	   of	   the	   HSA-­‐AuNC	   concentration.	   Therefore,	   HSA-­‐AuNCs	   have	   a	   larger	  
dynamic	   range	   and	   lower	   limit	   of	   detection	   than	   some	   other	   fluorescence-­‐based	  
methods	   of	   detecting	   L-­‐Dopa	   and	   related	   compounds[33–35].	   	   Further	   studies	   are	  
needed	  to	  explore	  the	  possibility	  of	  using	  HSA-­‐AuNCs	  as	  a	  platform	  for	  investigating	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